IGXT Share Price Performance
US$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
IntelGenx Technologies Corp. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
IGXT Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
IntelGenx Technologies Corp. Key Details
Last Reported Earnings
Mar 31, 2024
Next Reporting Earnings
n/a
- -0.063
- -66.03%
- -1,049.48%
- -103.7%
About IGXT
- Founded
- 2003
- Employees
- n/a
- CEO
- WebsiteView website
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
